Study Stopped
Protocol is being reevaluated by sponsor
An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
1 other identifier
observational
N/A
1 country
1
Brief Summary
The primary objective of the study is to examine the effectiveness of the Zephyr BioPatch in measuring position changes of a non-patient subject in a lab setting and to examine the effectiveness of the Zephyr BioPatch in measuring position changes of hospitalized patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Nov 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 1, 2015
CompletedFirst Posted
Study publicly available on registry
September 14, 2015
CompletedStudy Start
First participant enrolled
November 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedApril 6, 2017
April 1, 2017
3 months
September 1, 2015
April 4, 2017
Conditions
Outcome Measures
Primary Outcomes (2)
Body position
Body position will be classified as facing right, facing left, facing down (prone), or facing up (supine).
During a 2.5 hour lab observation
Body position
Body position when lying horizontally will be classified as facing right, facing left, facing down (prone), or facing up (supine).
During a 24 hospital observation
Secondary Outcomes (1)
Performance of the Zephyr BioPatch position output in hospitalized patients of varying body mass indexes (BMI)
During a 24 hospital observation.
Interventions
The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available. The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station.
Eligibility Criteria
The laboratory observation will consist of one non-patient subject (N=1). The hospital observation will consist of 18 patients (N=18) hospitalized at the Columbia University Medical Center on the general care floor at-risk for hospital-acquired pressure ulcers. The hospitalized subjects will be stratified into three groups. Six subjects with normal BMI classification (18.5 -24.9), six with overweight BMI classification (25.0-29.9), and six with overweight BMI classification (30.0-39.9) will comprise the study sample.
You may qualify if:
- Signed and dated informed consent by subject
- Male or female of any race
- At least 18 years of age
- Willingness to have study device attached during study participation
- Willingness to participate in all aspects of the study
You may not qualify if:
- Implanted pacemaker or defibrillator
- Allergy or sensitivity to ECG leads or similar types of adhesive
- History of hospital admission or a surgical procedure in the 60 days prior to study enrollment
- BMI \> 30.0
- Signed and dated informed consent by subject
- Male or female of any race
- At least 18 years of age
- Expected hospitalized admission on the general care floor for at least three days
- At risk for hospital-acquired pressure ulcers as defined by score on the Braden Scale of \< 18
- Willingness to have study devices attached during study participation
- Willingness to participate in all aspects of the study
- Implanted pacemaker or defibrillator
- Allergy or sensitivity to ECG leads or similar types of adhesive
- Subject will be sleeping in a chair or spending the majority of time in a chair
- BMI \> 39.9
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medtronic - MITGlead
Study Sites (1)
Columbia University Medical Center
New York, New York, 10032, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jason Adelman, MD, MS
Columbia University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2015
First Posted
September 14, 2015
Study Start
November 1, 2016
Primary Completion
February 1, 2017
Study Completion
February 1, 2017
Last Updated
April 6, 2017
Record last verified: 2017-04